Objective: To conduct a comprehensive, systematic review of studies assessing the significance of lipoprotein-associated phospholipase A2 in cardiovascular diseases (CVDs). Material and methods: A review of the literature was performed using the search term “Lipoprotein-associated phospholipase A2 (Lp-PLA2)” and each of the following terms: “cardiovascular risk,” “cardiovascular death,” “atherosclerotic disease,” “coronary events,”

Background: A significant proportion of heart failure (HF) patients have preserved ejection fraction (EF). Considering that inflammation and oxidative stress are involved in HF evolution, we investigated lipoprotein-associated phospholipase A2 (LpPLA2), an enzyme involved in these pathophysiologic processes in relation to EF. Methods and results: The study included 208 HF patients and 20 healthy controls. HF patients with preserved EF (HFpEF) represented

The value of the ultrastructural pattern of myeloperoxidase (MPO) and plateletperoxidase (PPO) staining is evaluated for the identification of the type of blastic cells during the acute transformation of a chronic myeloproliferative disorder. MPO and PPO are generally accepted as lineage specific markers for the detection of myeloid or megakaryocytic differentiation of the blast cells. The ultrastructural pattern of myeloperoxidase (MPO) and plateletperoxidase